S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
"Prepare for Five Years of Famine" (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
"Prepare for Five Years of Famine" (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
"Prepare for Five Years of Famine" (Ad)
Union Pacific 2nd railroad to drop push for one-person crews
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
"Prepare for Five Years of Famine" (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
"Prepare for Five Years of Famine" (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
"Prepare for Five Years of Famine" (Ad)
Union Pacific 2nd railroad to drop push for one-person crews
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
"Prepare for Five Years of Famine" (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
"Prepare for Five Years of Famine" (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
"Prepare for Five Years of Famine" (Ad)
Union Pacific 2nd railroad to drop push for one-person crews
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
"Prepare for Five Years of Famine" (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
"Prepare for Five Years of Famine" (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
"Prepare for Five Years of Famine" (Ad)
Union Pacific 2nd railroad to drop push for one-person crews
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:UTHR

United Therapeutics - UTHR Stock Forecast, Price & News

$219.94
+3.92 (+1.81%)
(As of 03/24/2023 08:52 PM ET)
Add
Compare
Today's Range
$213.03
$220.39
50-Day Range
$212.99
$265.92
52-Week Range
$173.21
$283.09
Volume
490,700 shs
Average Volume
552,902 shs
Market Capitalization
$10.18 billion
P/E Ratio
14.64
Dividend Yield
N/A
Price Target
$291.55

United Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
32.6% Upside
$291.55 Price Target
Short Interest
Healthy
2.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
0.51mentions of United Therapeutics in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$48.93 M Sold Last Quarter
Proj. Earnings Growth
10.64%
From $17.95 to $19.86 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.93 out of 5 stars

Medical Sector

43rd out of 995 stocks

Pharmaceutical Preparations Industry

11th out of 482 stocks


UTHR stock logo

About United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Stock News Headlines

The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
United Therapeutics (UTHR) Receives a Buy from Jefferies
UTHR Mar 2023 280.000 call
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Q4 2022 Liquidia Corp Earnings Call
10 Best Healthcare Stocks For Recession
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Company Calendar

Last Earnings
2/22/2023
Today
3/27/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
965
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$291.55
High Stock Price Forecast
$375.00
Low Stock Price Forecast
$230.00
Forecasted Upside/Downside
+32.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

Net Income
$727.30 million
Pretax Margin
49.09%

Debt

Sales & Book Value

Annual Sales
$1.94 billion
Cash Flow
$17.09 per share
Book Value
$105.24 per share

Miscellaneous

Free Float
40,561,000
Market Cap
$10.18 billion
Optionable
Optionable
Beta
0.62

Social Links


Key Executives

  • Martine A. RothblattMartine A. Rothblatt
    Chairman & Chief Executive Officer
  • Michael Ian Benkowitz
    President & Chief Operating Officer
  • James Christopher Edgemond
    Treasurer, Chief Financial & Accounting Officer
  • Paul A. MahonPaul A. Mahon
    Secretary, Executive VP & General Counsel
  • Dewey Steadman
    Head-Investor Relations













UTHR Stock - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 2 sell ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2023?

10 brokers have issued twelve-month target prices for United Therapeutics' stock. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they anticipate the company's share price to reach $291.55 in the next year. This suggests a possible upside of 32.6% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2023?

United Therapeutics' stock was trading at $278.09 at the beginning of the year. Since then, UTHR stock has decreased by 20.9% and is now trading at $219.94.
View the best growth stocks for 2023 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, February, 22nd. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.12 by $1.45. The biotechnology company earned $491.50 million during the quarter, compared to analyst estimates of $519.20 million. United Therapeutics had a trailing twelve-month return on equity of 16.30% and a net margin of 37.56%. The company's quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.35 EPS.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (6.29%), Renaissance Technologies LLC (5.14%), Avidity Partners Management LP (1.72%), Geode Capital Management LLC (1.45%), Assenagon Asset Management S.A. (1.32%) and Fuller & Thaler Asset Management Inc. (1.16%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $219.94.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.18 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $15.02 on an earnings per share basis.

How many employees does United Therapeutics have?

The company employs 965 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 3/27/2023 by MarketBeat.com Staff